Retrospective Chart Review Study of Pediatric Patients Treated With Korlym for Cushing Syndrome
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Hypercortisolism
- Sponsor
- Corcept Therapeutics
- Enrollment
- 2
- Locations
- 1
- Primary Endpoint
- Drug utilization patterns as assessed by chart review
- Status
- Terminated
- Last Updated
- 6 years ago
Overview
Brief Summary
This retrospective, multi-center, chart review study will collect patient data from medical charts of pediatric patients who have been treated with Korlym for Cushing's syndrome.
Detailed Description
This retrospective chart review study seeks to collect data from pediatric patients treated with Korlym (mifepristone) to help provide clinicians with some insight on the potential role of mifepristone in the treatment of pediatric patients with Cushing syndrome. Only sites that have been identified to have patients appropriate for this protocol will be invited to participate and contribute data on their patients Data to be collected from a retrospective chart review will include: * Patient demographics * Medical history * Pre and post treatment clinical assessments and laboratory results * Radiologic findings (if available) * Adverse events Data will be collected for all follow-up visits, up until the most recent encounter prior to IRB approval.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Pediatrics (age≤21 years) at time Korlym initiation
- •Considered to have a diagnosis of endogenous Cushing's syndrome by the healthcare provider
- •Received at least one dose of Korlym
- •Availability of pre-treatment (baseline) and follow-up data
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Drug utilization patterns as assessed by chart review
Time Frame: Length of Korlym therapy, up to 5 years
The retrospective review would analyze the drug utilization patterns of pediatric patients treated with Korlym
Secondary Outcomes
- Weight as assessed by chart review(Length of Korlym therapy, up to 5 years)
- Blood Pressure as assessed by chart review(Length of Korlym therapy, up to 5 years)